Triamcinolone acetonide hydrofluoroalkane inhalation - Abbott Laboratories

Drug Profile

Triamcinolone acetonide hydrofluoroalkane inhalation - Abbott Laboratories

Alternative Names: Azmacort HFA; Azmacort HFA-134a; KI 03216; RG 5016; Triamcinolone acetonide HFA inhalation - Abbott Laboratories; Triamcinolone acetonide HFA inhalation - Kos

Latest Information Update: 22 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis
  • Developer Abbott Laboratories
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 08 Oct 2013 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company known as AbbVie
  • 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top